ImaRx Therapeutics re-files for IPO

ImaRx Therapeutics, which is developing novel therapies for vascular disorders associated with blood clots, filed for an IPO with the SEC on Friday. The company originally attempted to go public in September 2006 before later withdrawing its offering. Now, the firm plans to sell 3 million shares at a range of $6.50 to $7.50, which would put its market cap at $63 million as compared to $211 million in its first go-around. The underwriter for the deal will now be Maxim Group, as opposed to CIBC World Markets. The company has filed to trade on the NASDAQ under the ticker IMRX.